The APOL2 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, designed to disrupt the APOL2 gene. This polyclonal knockout model provides a genetically diverse loss-of-function system that circumvents clonal variability, enabling robust functional studies of APOL2 in an epithelial colorectal cancer background. Researchers can utilize these cells to investigate the role of APOL2 in apoptosis, autophagy, and lipid metabolism without the confounding effects of residual wild-type gene expression. The heterogeneous nature of this population mirrors the genetic complexity of tumor environments, making it suitable for drug screening and pathway analysis.
HT29 cells are a well-established epithelial colorectal adenocarcinoma line harboring a mutant p53 allele, widely employed in oncology and gastroenterology research. Derived from a primary tumor, HT29 cells exhibit an undifferentiated phenotype under standard culture conditions but can undergo enterocytic differentiation when exposed to specific stimuli, offering a versatile platform for studies on intestinal barrier function and colorectal cancer progression. Their mutant p53 status lends relevance to investigations of chemoresistance and tumor suppressor pathways, particularly in the context of apoptosis evasion. As a model, HT29 recapitulates key features of colorectal tumors, including aberrant signaling and metabolic adaptations.
APOL2 encodes a member of the apolipoprotein L family, characterized by its lipid-binding capacity and association with high-density lipoproteins (HDL). A defining feature of APOL2 is its BCL2 homology 3 (BH3) domain, which mediates interactions with pro-survival BCL2 family proteins such as BCL2 and BAX. This interaction can neutralize anti-apoptotic protection, facilitating mitochondrial outer membrane permeabilization and caspase activation. APOL2 also engages with autophagy regulators like LC3 and p62/SQSTM1, linking nutrient and stress responses to cellular homeostasis. Upstream, APOL2 expression is governed by transcription factors including p53 and NF-??B, as well as interferon signaling and cellular stress pathways, positioning it at the intersection of survival, death, and metabolic control.
In HT29 colorectal adenocarcinoma cells, disruption of APOL2 uncouples critical apoptotic and autophagic nodes from upstream stressors, given the concurrent loss of p53-mediated transcriptional regulation. This knockout model permits dissection of APOL2-dependent cytoprotective mechanisms that may contribute to drug resistance and tumor cell longevity. The interplay between APOL2 and BCL2 family members is especially pertinent in colon cancer, where overexpression of anti-apoptotic proteins is common. By eliminating APOL2, researchers can assess its contribution to lipid trafficking and mitochondrial integrity, providing insights into how cancer cells balance death and survival decisions.
This polyclonal knockout product is suited for a breadth of translational applications, including functional genomics, apoptosis profiling, and autophagy flux analysis. Typical experimental workflows involve Western blotting for cleaved caspases and PARP to monitor apoptosis, flow cytometry with Annexin V/PI staining for cell death quantification, and colony formation assays to evaluate clonogenic survival. Autophagy can be assessed by LC3 turnover or p62 degradation, while co-immunoprecipitation enables validation of APOL2 interaction with BCL2. These assays position the cells as a tool for investigating colorectal cancer drug responses and identifying vulnerabilities linked to apoptotic machinery. For additional details or technical support, please contact Ascent Research.
